Lauren Santye, Assistant Editor

Top news of the day from across the health care landscape.

Investigators aim to determine whether Zika virus interferes with antiretroviral drugs that prevent mother-to-child transmission of HIV.

Report finds socioeconomic factors that increase vulnerability to HIV.

Tremfya is the first and only approved biologic that selectively blocks the interleukin-23 protein.

Tremfya found to achieve significantly clearer skin in moderate to severe plaque psoriasis.

Voluntary medical male circumcision may help to reduce the spread of HIV.

Top news of the day from across the health care landscape.

Emicizumab is administered subcutaneously only once per week compared with clotting factors administered intravenously 3 times per week.

Selective oral immunomodulator plus tenofovir alafenamide (Vemlidy) seeks functional cure in chronic HBV.

CTL019 is a chimeric antigen receptor T cell therapy.

Top news of the day from across the health care landscape.

The once-daily drug contains bictegravir and emtricitabine/tenofovir to treat adults with HIV-1.

Study finds the current reimbursement model for biosimilars needs to be adjusted to improve uptake.

No data were presented for treatment-naïve and pretreated adolescents with hepatitis B virus.

Investigators believe oral duvelisib may represent an important new treatment option for lymphoma patients.

Competition in HIV drug development affecting stock market.

Inhibiting particle release and infectivity could lead to a cure for HIV-1.

Top news of the day from across the health care landscape.

Merck will present late-breaker abstracts at upcoming IAS 2017 conference.

Cancer diagnoses delayed by an average of 9 days in patients with preexisting conditions.

Over-the-counter therapy could improve overall wellbeing in patients with multiple sclerosis.

The Biologics License Application for ibalizumab is under review for the treatment of multidrug resistant HIV-1.

Findings confirm no or negligible placental transfer of anti-TNF drug in women with rheumatoid arthritis.

Messaging based on patient medical records allow for more personalized care in HIV and other conditions.

Top news of the day from across the health care landscape.

Dutasteride (Avodart) increases blood sugar, A1C, and blood lipids.

The trial is the first to compare Xeljanz alone or in combination with MTX versus adalimumab plus MTX.

Boehringer Ingelheim seeks to launch its biosimilar to Humira.

Reports confirm 10 hepatitis A-related deaths in Detroit area over the past year.

Two KEYNOTE trials were placed on full clinical hold and 1 partial clinical hold.